Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830186 | 0.93 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL12810411 | 0.92 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL830848 | 0.87 | KMT2A (0.52) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL14606206 | 0.86 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL16270241 | 0.84 | KMT2A (0.52) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL13318793 | 0.84 | KMT2A (0.49) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL831222 | 0.83 | KMT2A (0.56) | SMN1; SMN2L3MBTL1LMNAKMT2ACYP1A2 | |
| SCHEMBL832097 | 0.82 | KMT2A (0.52) | SMN1; SMN2HPGDL3MBTL1LMNAKMT2A | |
| SCHEMBL4250581 | 0.82 | KMT2A (0.58) | SMN1; SMN2HPGDL3MBTL1LMNAKMT2A | |
| SCHEMBL831634 | 0.80 | TP53 (0.48) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45548-E1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-RE45548-E1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-RE45548-E1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-8846845-B2 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846845-B2 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846845-B2 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2298235-B1 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL LLC (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8409559-B2 | Functionalized drugs and polymers derived therefrom | Bezwada Biomedical, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8409559-B2 | Functionalized drugs and polymers derived therefrom | Bezwada Biomedical, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8409559-B2 | Functionalized drugs and polymers derived therefrom | Bezwada Biomedical, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100152272-A1 | FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152272-A1 | FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7691364-B2 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691364-B2 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691364-B2 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1931334-A2 | FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM | Bezwada Biomedical LLC (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030538-A2 | FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030538-A2 | FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060188547-A1 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060172983-A1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152272-A1 | FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM | OGFR, LOX, DDO | NPC1 3093/4885RAB9A 4857/4885SMN1; SMN2 3734/4885 |
| US-20060172983-A1 | Functionalized drugs and polymers derived therefrom | OGFR, LOX, OPRM1 | NPC1 2857/4885RAB9A 4852/4885SMN1; SMN2 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.